| Identification | Back Directory | [Name]
N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide | [CAS]
1439399-45-7 | [Synonyms]
Glutaminase-IN-3
N-[6-[4-(5-Amino-1,3,4-thiadiazol-2-yl)butyl]-3-pyridazinyl]-3-(trifluoromethoxy)benzeneacetamide
N-(6-(4-(5-Amino-1,3,4-Thiadiazol-2-Yl)Butyl)Pyridazin-3-Yl)-2-(3-(Trifluoromethoxy)Phenyl)Acetamide
N-(6-(4-(5-amino-1,3,4-thiadiazol-2-yl)butyl)pyridazin-3-yl)-2-(3-(trifluoromethoxy)phenyl)acetamide(WXC05490) | [Molecular Formula]
C19H19F3N6O2S | [MDL Number]
MFCD28411496 | [MOL File]
1439399-45-7.mol | [Molecular Weight]
452.45 |
| Chemical Properties | Back Directory | [density ]
1.437±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 50 mg/mL (110.51 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.93±0.70(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor with an IC50 of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657[1]. | [Biological Activity]
Glutaminase-IN-3 (compound 657) is a potent glutaminase inhibitor with an IC50 of 0.24 μM for Glutaminase 1 (GLS1). Glutaminase-IN-3 is extracted from patent WO2014089048A1, compound 657[1]. | [References]
[1]. Mark K. Bennett, et al. Treatment of cancer with heterocyclic inhibitors of glutaminase. WO2014089048A1. |
|
| Company Name: |
Wuxi AppTec
|
| Tel: |
022-59987777 13552403979 |
| Website: |
www.labnetwork.com |
|